Monte Rosa Therapeutics Quarterly Cash Flow Statement
NASDAQ: GLUEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Monte Rosa Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Monte Rosa Therapeutics generated -$44.1 million of operating cash flow and spent $4.7 million on capital expenditures. That left free cash flow of -$48.8 million, a free-cash-flow margin of -544.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Monte Rosa Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -43.40M | -44.50M | -46.13M | -27.08M | -12.29M | 46.88M | 13.44M | -23.86M | -30.31M | -31.97M | -33.25M | -34.88M |
| Net Income growth (YoY) | — | -194.92% | -443.34% | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 1.91M | 2.03M | 2.09M | 2.10M | 2.13M | 2.05M | 2.06M | 2.10M | 2.06M | 1.90M | 1.85M | 1.83M |
| Stock-Based Compensation | 5.97M | 5.95M | 4.31M | 4.36M | 4.89M | 5.30M | 4.47M | 4.28M | 4.50M | 4.87M | 4.07M | 4.47M |
| Change in Working Capital | -9.12M | -2.75M | -5.02M | 120.04M | -25.78M | -94.82M | 106.01M | -14.12M | 4.57M | -8.42M | 56.53M | 451.00K |
| Operating Cash Flow | -44.11M | -37.37M | -43.01M | 100.43M | -34.72M | -45.49M | 128.92M | -20.99M | -27.77M | -38.16M | 29.63M | -24.71M |
| Capital Expenditures | -4.72M | -1.87M | -767.00K | -651.00K | -1.70M | -1.59M | -183.00K | -399.00K | -2.02M | -1.38M | -1.69M | -1.66M |
| Investing Cash Flow | -28.86M | -261.00M | -65.07M | 38.14M | 25.32M | -100.23M | -30.90M | 37.75M | -61.16M | 9.85M | 14.30M | 35.63M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 3.21M | 328.33M | 29.62M | 348.00K | 365.00K | 14.00K | 608.00K | 15.00K | 98.02M | 246.00K | 25.17M | 1.10M |
| Net Change in Cash | -69.76M | 29.97M | -78.46M | 138.91M | -9.03M | -145.71M | 98.63M | 16.77M | 9.10M | -28.07M | 69.10M | 12.02M |
| Free Cash Flow | -48.84M | -39.24M | -43.78M | 99.78M | -36.41M | -47.08M | 128.74M | -21.39M | -29.79M | -39.55M | 27.95M | -26.36M |
This table shows 12 quarterly periods of Monte Rosa Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow GLUE's reporting calendar. What is a cash flow statement?